Bright Minds Biosciences' CEO, Ian McDonald, shares update on the company's multiple clinical trials.
Similar Posts
Rose Hill: Perfecting the Art of Psilocybin Cultivation with Charles Lazarus, Kevin Bourke and Domenic Suppa
In this episode, we delve into the fascinating realm of psilocybin cultivation, innovation, and exploration with the co-founding managing partners of Rose Hill, a pioneering company based in Jamaica.
Psychedelic Spotlight Interview with Douglas K. Gordon
In this episode of the Psychedelic Spotlight podcast, we connect…
Meet MindMed’s Interim CEO: Robert Barrow | My First Impressions & Comments
MindMed’s Interim CEO, Robert Barrow, has not made as many public appearances as opposed to MMED’s previous CEO, Jr Rahn.
As many of you know, almost two months ago, then MindMed’s CEO, JR Rahn, announced that he was stepping down, and he would be replaced immediately by Robert Barrow, then Chief Development Officer.
Since then, we have not had a lot of news from the company, and though we have heard from Barrow on previous Conference Calls, us the retail investors, have not had a chance to meet the man (at least digitally) as CEO yet.
That changed on August 3rd, when MNMD held a “fireside chat” over Zoom with Barrow, where we got to know him a little better, and he provided us with some new information.
In this video, we will play the most important clips and offer some commentary where necessary.
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedStock #MNMD
MindMed’s CEO RESIGNS! What’s NEXT for MMED / MNMD Stock? [ My Thoughts? ]
MindMed Changes CEO? Hey Guys! What a day it has been! Today, MindMed (MMED :NEO),
(MNMD: NASDAQ), and (MMQ: FRA) has announced that JR Rahn has stepped down as CEO of MindMed effective immediately. Chief Development Officer, Robert Barrow will assume the role while MindMed is considering possible candidates.
In this episode, we’ll cover several things.
1.What happened?
2.My general thoughts on the leadership change.
3.My thoughts on JR Rahn’s successes and his departure.
4.What Robert Barrow brings to the table as CEO.
Links:
MindMed changes leadership:
https://mindmed.co/news/press-release/mindmed-announces-chief-executive-officer-transition/
Robert Barrow background:
https://mindmed.co/team/robert-barrow-1/
https://www.newswire.ca/news-releases/mindmed-adds-chief-development-officer-with-fda-phase-2-psilocybin-clinical-trial-experience-862550304.html
General Reddit sentiment about MindMed’s leadership change:
https://www.reddit.com/r/MindMedInvestorsClub/comments/nvwtou/expected_this_sub_to_be_on_fire_this_morning_but/
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MNMD #MindmedNews
Numinus & Cybin Forge MASSIVE DEALS ( NUMI / CYBN )
BIG news for Cybin Inc. (CYBN: NEO) (CLXPF: OTC) and Numinus Wellness (NUMI: NEO)
(LKYSF: OTC).
First and foremost, Numinus announced that the company acquired NCT, a Toronto-based, fully operational neurology center with 13 doctors, 8 allied health staff, nurse practitioners, and physician assistants. NCT and Numinus plan to establish the first center for excellence in psychedelic neurology.
Speaking of centers of excellence, Cybin entered into an agreement with a company called Greenbrook TMS to establish mental health centers of excellence in order to facilitate R & D of psychedelic compound-based therapeutics for patients suffering from depression.
Why is this big news? Watch till the end to find out!
In other news, we are glad to announce that The Psychedelic Investor has entered into a collaboration with Psychedelic Spotlight, one of the biggest news sources for psychedelic-related news.
Twice a month, I will be discussing some of the major industry news among other psychedelic industry experts in Psychedelic Spotlight’s segment titled: “Spotlight Roundup”.
Check out my first appearance on their podcast by clicking the link below!
https://www.youtube.com/watch?v=UKGFXnsOlr8
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Timestamps
0:00 -Intro
2:40 – Numinus Acquisition of Neurology Center of Toronto
9:55 -Cybin Enters Agreement with Greenbrook
Links:
NUMINUS WELLNESS TO ACQUIRE NEUROLOGY CENTRE OF TORONTO, PLANS TO CREATE CENTRE FOR PSYCHEDELIC NEUROLOGY:
https://thepsychedelicinvestor.com/2021/07/06/numinus-wellness-to-acquire-neurology-centre-of-toronto-plans-to-create-centre-for-psychedelic-neurology/
CYBIN (NEO: CYBN, OTC: CLXPF) ENTERS INTO COLLABORATION AGREEMENT WITH GREENBROOK TMS TO ESTABLISH MENTAL HEALTH CENTERS OF EXCELLENCE:
https://thepsychedelicinvestor.com/2021/07/08/cybin-enters-into-collaboration-agreement-with-greenbrook-tms-to-establish-mental-health-centers-of-excellence/
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Numinus #Cybin #NUMIStock
Field Trip And Wesana Make Major Moves | FTRP, WESA
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Join our Newsletter (scroll to the bottom of the page and sign up):
https://psychedelicspotlight.com/
Wesana Health May Sell Clinics to Focus Solely on Drug Development: An Analysis
https://psychedelicspotlight.com/wesana-health-may-sell-clinics-to-focus-solely-on-drug-development-an-analysis/
Why Field Trip Health Is Dividing in Two — and What This Means for Investors
https://psychedelicspotlight.com/field-trip-health-dividing-two-companies-reunion-neuroscience/
In today’s episode of the Psychedelic Investor, I discuss two major stories. First, is the news that Field Trip Health (Nasdaq: FTRP, TSX: FTRP) will be splitting into two separate companies.
Next, Wesana Health (CSE: WESA, OTCQB: WSNAF) announced that they are considering selling all of their non-drug development assets, including their Psychedelic Therapy clinics.
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PSYCBiz
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@psycbiz
@psycspotlight
To read more about the Field Trip situation: https://psychedelicspotlight.com/field-trip-health-dividing-two-companies-reunion-neuroscience/
To read more about the Wesana situation: https://psychedelicspotlight.com/wesana-health-may-sell-clinics-to-focus-solely-on-drug-development-an-analysis/
Field Trip Press Release: https://www.globenewswire.com/news-
release/2022/04/28/2432105/0/en/Field-Trip-Health-Ltd-Announces-Intention-to-Separate-the-Field-Trip-Discovery-and-Field-Trip-Health-Divisions-Into-Two-Independent-Public-Companies.html
Wesana Press Release: https://ir.wesanahealth.com/news-events/press-releases/detail/41/wesana-announces-singular-focus-on-drug-development
Field Trip Health:
In a surprise move, Field Trip Health Ltd. announced on Thursday that they will be separating their company into two independent publicly traded entities.
Assuming the ratification of shareholders and regulatory approval, come July 2022, Field Trip Health will be no more. From its ashes will rise Reunion Neuroscience Inc, and Field Trip Health and Wellness Ltd.
Reunion will be the successor to Field Trip’s Discovery division, which was the part of the company which worked on next-generation psychedelics. This includes FT-104, a psilocybin-like compound that is a prodrug to 4-HO-DiPT, and the company’s FT-200 series of psychedelics, which they call third-generation.
Wesana:
On Thursday, Wesana Health made a major announcement. Following a planned strategic review of their assets, Wesana is considering options “including, but not limited to, a sale of all the assets under the care delivery division,” including all of their psychedelic therapy clinics.
The core reasoning, according to the press release, is that Wesana wants to focus its efforts entirely on its drug development division.
Prior to this announcement, Wesana was operating under a philosophy centered on “developing the novel therapies of tomorrow and delivering new care paradigms today.” If this strategic review does result in the sale of their clinics and other today-focused ventures, then Wesana will be decidedly much more focused on tomorrow.
@psycspotlight #wesana #psychedelicstocks #thepsychedelicinvestor